Img header logo

Environment

Toward Creating a Water Recycling-oriented Society

リード文

The availability of high-quality fresh water is one of the important factors for us in conducting business activities. We are making efforts for reducing water use so as to mitigate the load on limited water resources.

ONO PHARMACEUTICAL CO.,LTD., ONO PHARMACEUTICAL CO.,LTD., system

Analysis and Evaluation of Water-related Risk and Opportunity

As for water risks, the Environmental Management Committee leads and conducts surveys on the risks, and identifies/analyzes/evaluates the business risks. Risk evaluation at important sites that use large volumes of water is conducted using the WRI AQUEDUCT risk assessment tool of the World Resource Institute. As of the end of FY2019, none of our company’s important sites operate or conduct water intake in areas categorized as being at “extremely high risk” for water stress*. We continue to operate in areas where it is possible to use good quality fresh water as needed for business operations, and our business activities are therefore not affected. In the Water Security survey conducted by CDP, a U.K.-based nonprofit organization, we received “B” in FY2018, “A-” in FY 2019 and FY2020, and “A”, a highest rating, in FY2021.

*Water intake at factories and research institutes accounts for approximately 90% of the total use (FY2020), and for each sites, water stress categories are as follows. Low-medium: Yamaguchi Plant, Minase Research Institute, Fukui Research Institute, Joto Pharmaceutical Product Development Center, Medium to high: Fujiyama Plant, Tsukuba Research Institute.
 Note that ONO Pharma Korea is located in the “high risk” area, but its main business is clinical development and sales, so their water use is mainly domestic water at the business office, not factories and research facilities that use relatively large amounts of water.

Risk Factors Period Details Impact Management Method
Regulatory
risk
Restrictions on use of good quality fresh water Long-term Use of good quality fresh water becomes impossible, restricting production and research activities. Increase in operating costs
  1. Assurance of pharmaceutical products supplied
  2. Risk diversification due to establishment of new facilities
Risk from physical impact Rationing/shortage of good quality fresh water Long-term Use of good quality fresh water becomes impossible, restricting production and research activities. Increase in operating costs
  1. Assurance of pharmaceutical products supplied
  2. Risk diversification due to establishment of new facilities
Decline in water quality Long-term Use of good quality fresh water becomes impossible, restricting production and research activities. Increase in operating costs
  1. Investment in plant and equipment
  2. Water quality analysis and management
Flooding and/or heavy rain disaster Long-term Facilities are flooded due to flooding or heavy rainfall in the vicinity of a production site. Increase in operating costs
  1. Assurance of pharmaceutical products supplied
  2. Investment in plant and equipment
Other risks Reputation risk Short-term A poor external evaluation of our handling of water exerts an adverse impact on the share price. Decline in share price Appropriate external publicity on the results of our activities
Opportunity Factors Period Details Impact Management Method
Opportunity
from
physical
impact
Water
shortage
Long-term Demand increases for existing pharmaceutical products that can be used without water, or new drug development opportunities lead to positive impact on revenue. Increased demand for existing drugs and services, new drugs and services
  1. Changes in formulation of existing pharmaceutical products
  2. New Drug Development

We have posted details such as the water-related risks and opportunities, water intake and wastewater volumes at CDP Water (Japanese only). They can be confirmed at the CDP website (A CDP ID is required). 

ONO PHARMACEUTICAL CO.,LTD., ONO PHARMACEUTICAL CO.,LTD., system

Progress Towards a Water Recycling Society

To achieve our medium-term environmental target of the Environmental Vision for the “Realization of a water recycling society” of “Reducing water resource consumption (water intake) per production volume unit by 15% by FY 2030 (compared to FY 2017),” we have set an annual goal to "Reduce water resource consumption (water intake) below that of the previous year" and we are working vigorously to reduce water consumption in business activities. The volume of water intake in FY 2020 was 245.6 km3, a 17.2% reduction (51.1 km3) compared to FY 2019, and we therefore achieved the target for the fiscal year.
Specific initiatives to reduce water consumption include the following: installation of highly airtight doors at the plant and stopping the use of running water traps as insect repellent, reduction of cooling water by adjusting the preset temperature of the heat drain tank, stopping the spraying of water or changing the preset temperature of the spraying water on air-cooling chillers and total heat exchangers in the laboratory. We also install water-saving sanitary equipment when a site is expanded, reconstructed, or renewed. In addition, Fukui Research Institute has installed a water recycling system to reduce water intake.
Incidentally, the water intake per production volume unit in FY 2020 increased by 4.6% compared to FY 2017. This is mainly due to a decrease in the number of boxes produced, which is used as a denominator for calculation. High-dose formulations of main products, which were not available in FY 2017, were added in FY 2018. The number of boxes produced, which is the denominator for calculation, was greatly reduced, because the number of boxes produced was apparently calculated as smaller even with the same amount of production.
 

Water intake (water resource consumption) and water intake per production volume unit

graph
  • * From FY2019, the head office and other domestic offices have been added retroactively to FY2017.

Wastewater

graph
  • * Sites where data on water consumption and wastewater volume were collected: Fujiyama Plant, Joto Pharmaceutical Product Development Center, Yamaguchi Plant (added from FY 2018), Minase Research Institute, Fukui Research Institute, Tsukuba Research Institute, Head Office, sales offices and other offices, etc.
    From FY2019, the head office and other domestic offices have been added retroactively to FY2017.
Water intake and wastewater volume by site (unit: thousand m3)
Site
name
River
in
the
area
Wastewater
drainage
destination
FY2016 FY2017 FY2018 FY2019 FY2020
Water
intake
volume
Waste-
water
volume
Water
intake
volume
Waste-
water
volume
Water
intake
volume
Waste-
water
volume
Water
intake
volume
Waste-
water
volume
Water
intake
volume
Waste-
water
volume
Fujiyama Plant Fuji River River 195.7 128.9 205.6 148.6 240.2 178.4 185.0 145.1 157.8 125.0
Joto Pharmaceutical Product Development Center Yodo River Sewer 7.2 7.2 5.5 5.5 6.0 6.0 5.1 5.1 4.6 4.6
Yamaguchi Plant Fushino River River - - - - 8.2 8.2 18.1 18.1 18.6 17.7
Minase Research Institute Yodo River Sewer 45.2 45.2 51.3 51.3 41.2 41.2 39.1 39.1 33.7 33.7
Fukui Research Institute Kuzuryu River Sewer 39.4 7.5 38.7 5.2 31.3 5.0 27.3 5.7 13.7 2.6
Tsukuba Research Institute Lake Kasumigaura Sewer 10.9 10.9 8.1 8.1 6.0 6.0 7.1 7.1 7.2 7.2
Head Office and other sites in Japan (including tenant locations) Rivers/lake in the areas where major business sites are located*1 Sewer - - 15.9 15.9 15.1 15.1 15.0 15.0 10.0 10.0
total 298.4 199.7 325.1 234.6 348.0 259.9 296.7 235.2 245.6 200.8
  • *1 Rivers/Lake in the areas where major business sites are located: Toyohira River, Okura River, Arakawa River, Sakawa River, Kiso River, Lake Biwa, Yodo River, Ota River, Yoshino River, Naka River
ONO PHARMACEUTICAL CO.,LTD., ONO PHARMACEUTICAL CO.,LTD., system